Evidence map›Paper›PMID 35155556›Full record

ArticleFrontiers in surgery2022

Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma.

Huasheng Wu, Fadian Ding, Meitai Lin, Zheng Shi, Zhengzhou Mei, Shaoqin Chen, Chao Jiang, Huabin Qiu, Zhenhua Zheng, Youting Chen and 1 more

Abstract read
In one paragraph

Article in Frontiers in surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huasheng WuDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.
Fadian DingDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Meitai LinDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.
Zheng ShiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Zhengzhou MeiDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.
Shaoqin ChenDepartment of Intensive Care Unit, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China.
Chao JiangDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.
Huabin QiuDepartment of Gastroenterology, San Ming First Hospital, Sanming, China.
Zhenhua ZhengDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.
Youting ChenDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Peng ZhaoDepartment of Hepatobiliary Surgery, San Ming First Hospital, Sanming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to assess the clinical utility of the advanced lung cancer inflammation index (ALI) as a prognostic indicator for patients with cholangiocarcinoma (CCA) and construct a prognostic nomogram based on ALI.

methodsA total of 97 CCA patients who received radical resection were included. The optimal cut-off point for ALI was identified by X-tile analysis. COX regression analysis were used to identify risk factors of overall survival (OS) and disease-free survival (DFS). A predictive nomogram for DFS was constructed.

resultsThe optimal cut-off value for preoperative ALI was 31.8. 35 (36.1%) patients were categorized into the low-ALI group and 62 (63.9%) patients into the high-ALI group. Low ALI was independently associated with hypoproteinemia and lower body mass index (BMI) (all

conclusionsALI may be useful for prognosis assessment for patients with CCA.

Indexed as

advanced lung cancer inflammation index nomogramcholangiocarcinomaMLRNLRprognosisSII

Identifiers

PMID35155556
PMCPMC8828638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.